首頁 > 市場調查報告書 > 製藥

感染疾病

全球流感治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1408984

全球流感治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Influenza Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 239 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2030 年，全球流感治療市場的市場規模將從 2022 年的 61.3 億美元達到近 73.4 億美元，2023-2030 年研究期間CAGR為 2.27%。

流感治療主要著重於緩解症狀和預防併發症，如流行性感冒，俗稱流感。它是由病毒引起的，抗生素對病毒感染無效。經常建議使用抗病毒藥物來減輕流感相關症狀的強度和持續時間。這些藥物透過抑制流感病毒在體內的複製來發揮作用。

市場動態

流感治療市場受到幾個關鍵因素的推動，包括流感的季節性，導致流感高峰季節的需求持續穩定。全球人口的增加，特別是在人口稠密的地區，增加了流感爆發的可能性，從而推動了市場的成長。抗病毒藥物和治療方法的持續研究和開發在滿足創新解決方案的需求方面發揮關鍵作用，特別是面對新出現的流感病毒株和潛在的大流行病。促進流感疫苗接種的政府措施和公共衛生運動有助於塑造市場，並強調預防措施的重要性。注重早期診斷和治療的意識努力也在市場擴張中發揮作用。慢性病的流行增加了嚴重流感併發症的風險，進一步推動了對有效治療的需求。醫療基礎設施、政策和經濟狀況等因素都會影響市場，流感病毒的不斷進化需要適應性的治療策略。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球流感治療市場的各個細分市場進行了包容性評估。流感治療產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲流感治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。流感治療市場的主要參與者包括NATCO Pharma Limited、諾華公司、F. Hoffmann-La Roche Ltd、BioCryst Pharmaceuticals, Inc.、賽諾菲、GSK plc.、Viatris Inc. (MYLAN)、Teva Pharmaceutical Industries Ltd.、 Daiichi三共株式會社、阿斯特捷利康。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：流感治療公司的競爭格局

流感治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
NATCO Pharma Limited

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche Ltd

公司簡介
公司收入
產品
最近的發展

BioCryst Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

GSK plc.

公司簡介
公司收入
產品
最近的發展

Viatris Inc. (MYLAN)

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd.

公司簡介
公司收入
產品
最近的發展

Daiichi Sankyo Company Ltd.

公司簡介
公司收入
產品
最近的發展

AstraZeneca

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113271

The global demand for Influenza Treatment Market is presumed to reach the market size of nearly USD 7.34 BN by 2030 from USD 6.13 BN in 2022 with a CAGR of 2.27% under the study period 2023 - 2030.

Influenza treatment primarily focuses on alleviating symptoms and preventing complications, as influenza, commonly known as the flu. It is caused by viruses, and antibiotics are ineffective against viral infections. Antiviral medications are frequently recommended to mitigate the intensity and duration of symptoms associated with influenza. These medications work by inhibiting the replication of the influenza virus in the body.

MARKET DYNAMICS

The influenza treatment market is driven by several key factors, including the seasonal nature of influenza, leading to a consistent demand during peak flu seasons. The increasing global population, especially in densely populated regions, contributes to the likelihood of flu outbreaks, fueling the market's growth. Ongoing research and development in antiviral medications and treatment methods play a pivotal role in addressing the need for innovative solutions, particularly in the face of emerging influenza strains and potential pandemics. Government initiatives and public health campaigns promoting flu vaccination contribute to shaping the market, emphasizing the importance of preventive measures. Awareness efforts focusing on early diagnosis and treatment also play a role in market expansion. The prevalence of chronic diseases, which elevate the risk of severe influenza complications, further drives the demand for effective treatments. Factors such as healthcare infrastructure, policies, and economic conditions can influence the market, and the continuous evolution of influenza viruses necessitates adaptable treatment strategies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of influenza treatment. The growth and trends of influenza treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the influenza treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

Peramivir
Zanamivir
Baloxavir Marboxil
Oseltamivir Phosphate
Others

By Route Of Administration

Oral
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Influenza Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Influenza Treatment market include NATCO Pharma Limited, Novartis AG, F. Hoffmann-La Roche Ltd, BioCryst Pharmaceuticals, Inc., Sanofi, GSK plc., Viatris Inc. (MYLAN), Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company, Ltd., AstraZeneca. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . INFLUENZA TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL INFLUENZA TREATMENT MARKET ANALYSIS BY TREATMENT

5.1 Overview by Treatment
5.2 Historical and Forecast Data
5.3 Analysis by Treatment
5.4 Peramivir Historic and Forecast Sales by Regions
5.5 Zanamivir Historic and Forecast Sales by Regions
5.6 Baloxavir Marboxil Historic and Forecast Sales by Regions
5.7 Oseltamivir Phosphate Historic and Forecast Sales by Regions
5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL INFLUENZA TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1 Overview by Route of Administration
6.2 Historical and Forecast Data
6.3 Analysis by Route of Administration
6.4 Oral Historic and Forecast Sales by Regions
6.5 Others Historic and Forecast Sales by Regions

7 . GLOBAL INFLUENZA TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL INFLUENZA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE INFLUENZA TREATMENT COMPANIES

9.1. Influenza Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF INFLUENZA TREATMENT INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. NATCO Pharma Limited
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Novartis AG
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. F. Hoffmann-La Roche Ltd
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. BioCryst Pharmaceuticals Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Sanofi
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. GSK plc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Viatris Inc. (MYLAN)
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Teva Pharmaceutical Industries Ltd.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Daiichi Sankyo Company Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. AstraZeneca
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments